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Background: A considerable proportion of IgAN patients present with histological vasculitic/crescentic lesions in
glomeruli, indicating activation of vascular inflammation. Using sVCAM-1, a well-proven marker for endothelial injury
under inflammatory processes, we investigated vascular injury and its association with clinical and pathological
manifestations in IgAN patients.
Methods: In this study, 327 biopsy-proven IgAN patients and 55 healthy controls were enrolled. The Oxford
classification and two variables, Active Crescentic Lesion Percentage (ACLP) and Chronic Glomerular Lesion
Percentage (CGLP), were used for evaluating pathological lesions. Human Umbilical Vein Endothelial Cells were
treated with 25-400 ug/ml IgA1. sVCAM-1 in plasma and culture supernatant were measured by ELISA.
Results: Plasma sVCAM-1 in IgAN patients was significantly higher than healthy controls. In patients with IgAN,
plasma sVCAM-1 was significantly correlated with eGFR, 24h urine protein excretion, tubular atrophy/interstitial
fibrosis lesion and ACLP, but not CGLP. Meanwhile, compared to healthy volunteers, IgA1 from IgAN patients
showed a tendency to increase the HUVECs supernatant sVCAM-1 expression. And IgA1 induced the sVCAM-1
increasing from HUVECs in time- and dose-dependent manner.
Conclusions: We found increased plasma sVCAM-1 in IgAN patients and its association with severe clinical and
pathological manifestations, which might be partly resulted from effect of IgA1 to endothelial cells.
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IgA nephropathy (IgAN) is the most common primary
glomerulonephritis worldwide [1]. Except for the most
characteristic finding, that is glomerular mesangial area
deposition of IgA, a considerable proportion of IgAN
patients present with histological vasculitic/crescentic
lesions in glomeruli, accompanied by distinct neutrophils
and/or monocytes infiltration, indicating the activation
of vascular inflammation in IgAN [2]. Clinically, many
patients with IgAN suffer hypertension at a relative
young age, and some present with secondary malignant
hypertension. In China, IgAN was reported as one of the
major causes of secondary malignant hypertension,
accounting for one-third of all secondary causes and* Correspondence: hongzh@bjmu.edu.cn
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reproduction in any medium, provided the or40% of glomerular causes [3,4]. Although clinical and
histological observations strongly indicated the involve-
ment of vascular injury in IgAN, the pathogenesis of the
vascular injury in IgAN is still unknown.
Vascular cell adhesion molecule 1 (VCAM-1) is endo-
thelial ligand for integrins expressed on leukocytes and
platelets, with the function of facilitation endothelial
adhesion of circulating leukocytes. The endothelial
expression of VCAM-1 is increased in response to
inflammatory cytokines [5]. And the soluble ectodomain
of VCAM-1 (sVCAM-1) is proteolytically released from
the endothelial cell surface into the circulation upon
endothelial activation and injury. Elevated plasma
sVCAM-1 level was reported in many diseases, such as
coronary and peripheral atherosclerosis, diabetes mel-
litus, systemic lupus erythematosus, Crohn's disease and
so on [6-9]. Soluble vascular adhesion molecule-1 is now
a well-proven marker for endothelial injury under
inflammatory processes.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IgAN, elevated plasma sVCAM-1 level was also observed
and reported to be associated with impaired renal function
[10-13]. But most studies were unable to state the major
cause of high plasma levels of sVCAM-1, which could be
either explained by increased production or decreased
clearance. Recently, A.E.M. Stinghen et al. reported that
exposure of endothelial cells to uremic plasma resulted in a
time- and CKD-stage-dependent increased expression of
sVCAM-1, suggesting a link between vascular activation,
systemic inflammation and uremic toxicity [14]. IgA
nephropathy, a study is needed to explore the cause of high
plasma levels of sVCAM-1 and its association with vascular
inflammation.
In the present study, we investigated the association of
sVCAM-1 with clinical and pathological characteristics
in patients with IgAN, and further detected the effect of
IgA1 molecules on sVCAM-1 production by cultured
endothelial cells in vitro to explore the mechanism of
vascular inflammation in IgAN.
Methods
Study population
In the present study, a total of 382 subjects were enrolled,
including 327 IgAN patients and 55 healthy volunteers with
normal urine analysis and blood pressure. Diagnoses of
IgAN were biopsy proven and confirmed by granular
deposition of IgA in the glomerular mesangium by im-
munofluorescence detection, as well as by the deposition of
electron dense material in mesangial ultra-structural
examination. Patients with Henoch-Schonlein purpura,
systemic lupus erythematosus, and chronic hepatic diseases
were excluded by detailed clinical and laboratory examina-
tions. In addition, 19 patients with minimal change disease
(MCD), 30 with membranous nephropathy (MN) and 25
with lupus nephritis were recruited as control patients with
other glomerular injury.
On the morning of renal biopsy and the inclusion in the
study, plasma (EDTA) from patients and healthy volunteers
was collected, divided into aliquots, and stored at −80°C
pending the measurement of sVCAM-1. Clinical manifesta-
tions at the time of renal biopsy, including serum IgA level,
serum creatinine level, 24 hours urine protein excretion,
history of hypertension and history of gross hematuria were
collected from the clinical record. The glomerular filtration
rate (GFR) of IgAN patients was calculated by the Modified
Glomerular Filtration Rate Estimating Equation for Chinese
[15]. Histologically, the Oxford classification was used for
evaluating the pathological lesions [16]. Additionally, we
used two indices to grossly distinguish the active and
chronic glomerular lesion, which were Active Crescentic
Lesion Percentage (ACLP) and Chronic Glomerular Lesion
Percentage (CGLP). ACLP included the glomerular bearing
cellular crescents, fibrocellular crescents and fibrinoidnecrosis. CGLP included the glomerular having global
sclerosis, segmental sclerosis and fibrous crescents.
The protocol for this study was approved by the Medical
Ethics Committee of Peking University and informed
written consent for this study was obtained from every
participant.
Detection of plasma sVCAM-1
Plasma sVCAM-1 levels were determined using commer-
cial ELISA kits according to the manufacturer’s specifica-
tions (R&D Systems, Minneapolis, MN, USA).
Isolation of human plasma IgA1
Whole IgA1 was isolated by jacalin affinity chromatography
from plasma as previous described [17]. In the present
study, another small population, including 12 biopsy
approved IgAN patients and 12 healthy controls, was used
for IgA1 isolation. Plasma from the 24 individuals was
introduced to jacalin affinity chromatography, one by one.
Briefly, 3ml plasma from every subject were diluted 1:3 with
0·01 mol/l phosphate buffered saline (PBS), filtered through
a 0.22 um Corning syringe filter (Corning Glass Works,
Corning, NY, USA) and then applied to a jacalin column,
which was prepared with commercially available jacalin
immobilized on cross-linked 4% beaded agarose (Pierce
Chemical Company, Rockford, IL, USA) with an IgA1
binding capacity of more than 2 mg/ml. The column was
equilibrated with 0.01 mol/l PBS and IgA1 was eluted with
0.1 mol/l melibiose (Sigma, St. Louis, MO, USA) in
0.01 mol/l PBS. The eluted sample concentration and
removal of melibiose were performed by pressure ultra-
filtration using Vivaspin (Cat No: VS2021, Sartorius,
Goettingen, Germany). The total protein concentrations
of isolated IgA1 samples from the 24 individuals were
tested using DC Protein Assay (Bio-Rad, Hercules, CA,
USA). IgA1 was then aliquoted and stored at −80°C
pending cell culture experiments.
Culture of endothelial cells with IgA1
Primary Human Umbilical Vein Endothelial Cells
(HUVECs) and all the cell culture media, fetal bovine
serum, supplements and extra cellular matrix were
purchased from ScienCellTM Corporation (ScienCellTM,
Carlsbad, CA, USA). Cells were cultured according to
the manufacturer’s specifications, in Endothelial Cell
Medium (ECM) supplemented with Endothelial Cell
Growth Supplement (EsCGS), 5% fetal bovine serum,
penicillin G (100 U/ml) and streptomycin (100 U/ml) at
37°C in a humidified 5% CO2 incubator. HUVECs were
seeded into 24-well plates precoated with 1 ug/cm2 Poly-
L-Lysine (PLL) before experiment. After 12 h of serum
starving, HUVECs were treated with 400 ug/ml whole
IgA1 from 24 individuals, including 12 IgAN patients
and 12 healthy controls (we did not pool isolated IgA1








macroscopic hematuria with 101 (30.9%)
without 226 (69.1%)
proteinuria more than 1 g/24 h 211 (64.5%)
less than 1 g/24 h 116 (35.5%)
hypertension with 124 (37.9%)
without 203 (62.1%)
Oxford classification M M0 123 (37.6%)
M1 204 (62.4%)
E E0 141 (43.1%)
E1 186 (56.9%)
S S0 68 (20.8%)
S1 259 (79.2%)
T T0 253 (77.4%)
T1 39 (11.9%)
T2 35 (10.7%)
Table 2 Correlations between plasma levels of sVCAM-1
and clinical and histological manifestations of patients
with IgAN
eGFR UPE IgA UA SBP DBP ACLP CGLP
ρ* −0.197 0.198 0.062 0.117 0.077 0.053 0.182 0.054
p value <0.001 <0.001 0.293 0.038 0.168 0.344 0.001 0.327
* Pearson's correlation coefficient.
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together). For dose-dependent assay, 25-400 ug/ml whole
IgA1 from one IgAN patient were used. For time-
dependent assay, HUVECs were treated with 200 ug/ml
whole IgA1 from one IgAN patient for 6–48 hours.
Detection of supernatant sVCAM-1
Supernatant samples were separated from culture after 48h
of incubation (except for time-dependent assay, in which
6-48 h were used) and were stored at −80°C until assay.
Supernatant sVCAM-1levels were measured by ELISA as
described above.
Statistical analysis
Descriptive statistical analyses were performed with
SPSS10.0 software (SPSS Inc., USA). Continuous variables
were compared by unpaired Student’s t test or ANOVA
(ANalysis Of VAriance between groups). Dichotomous and
polychromous data were analyzed by the χ2 test. Correla-
tions were performed by the Spearman rank test (ρ).
Results are expressed as means ± SD. A p value of less than
0.05 was considered statistically significant.
Results
Clinical and pathological manifestations of patients with
IgAN
In our study, 327 IgAN patients were involved. The
main clinical and pathological manifestations of them
were summarized in Table 1. Of them, 155 were males and
172 were females. The age at renal biopsy was 32.9±10.7
year old. And 30.9% patients were with a history of macro-
scopic hematuria, 37.9% with a history of hypertension and
64.5% with moderate and severe proteinuria (>1 g/24 h).
eGFR were 85.43±30.29 ml/min.
Plasma levels of sVCAM-1 in the IgAN patients
The plasma levels of sVCAM-1 did not significantly dif-
fer between males and females in IgAN patients. Patients
with IgAN presented higher plasma levels of sVCAM-1
than that in healthy controls (726.66±290.35 ng/ml Vs
520.23±137.51 ng/ml, p<0.001). In patients with MCD
and MN, plasma levels of sVCAM-1 showed no diffe-
rence to healthy controls (MCD: 485.09±203.37 ng/ml,
MN: 511.49±278.36 ng/ml), while patients with LN pre-
sented higher levels of sVCAM-1 (LN: 958.53±601.49,
p value versus healthy controls=0.001), which was simi-
lar to that found in IgAN patients.
Correlations between plasma levels of sVCAM-1 and
clinical characteristics of patients with IgAN
In patients with IgAN, the plasma levels of sVCAM-1 were
significantly correlated with eGFR (ρ=−0.197, p<0.001),
24 h urinary protein excretion (UPE) (ρ=0.198, p<0.001)
and uric acid (UA) (ρ=0.117, p=0.038) (Table 2), but notserum IgA levels, systolic blood pressure and diastolic
blood pressure at the time of renal biopsy. Although the
blood pressure at the time of renal biopsy did not corre-
lated with plasma sVCAM-1 levels, IgAN patients with
hypertension still had significantly elevated plasma
sVCAM-1 levels than those without (786.40±339.43 ng/ml
Vs 690.17±249.75 ng/ml, p<0.001) (Figure 1a). Both group
of patients, with or without hypertension, presented with
higher plasma sVCAM-1 levels than healthy controls (with-
out hypertension Vs healthy controls: 690.17±249.75 ng/ml
Vs 520.23±137.51 ng/ml, p<0.01; with hypertension Vs
healthy controls: 786.40±339.43 ng/ml Vs 520.23±137.51
ng/ml, p<0.01) (Figure 1a). The plasma levels of sVCAM-1
showed no difference between IgAN patients with or with-
out gross hematuria history (Figure 1b).
Figure 1 Scatter plot showing distribution of plasma sVCAM-1 levels of enrolled individuals according to with or without hypertension
(HT), and with or without gross hematuria history (GH), respectively. a. Both group of IgAN patients, with or without hypertension,
presented with higher plasma sVCAM-1 levels than healthy controls (without hypertension Vs healthy controls: 690.17±249.75 ng/ml Vs 520.23
±137.51 ng/ml, p<0.01; with hypertension Vs healthy controls: 786.40±339.43 ng/ml Vs 520.23±137.51 ng/ml, p<0.01). IgAN patients with
hypertension had significantly elevated plasma sVCAM-1 levels than those without (786.40±339.43 ng/ml Vs 690.17±249.75 ng/ml, p<0.01).
b. Plasma levels of sVCAM-1 showed no difference between IgAN patients with or without gross hematuria history.
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pathological characteristics of patients with IgAN
Patients with higher scores in the variable tubular atrophy/
interstitial fibrosis showed significantly higher sVCAM-1
(T2:T1:T0=941.97±339.95 ng/ml: 699.27±213.43 ng/ml:701.
10±281.76 ng/ml, p<0.001), patients with higher scores in
the variables mesangial hypercellularity showed relative
higher sVCAM-1, although do not reach the statistic signifi-
cance (M1:M0=749.88±279.76 ng/ml: 688.14±304.38 ng/ml,
p=0.062) (Table 3). Furthermore, the plasma levels of
sVCAM-1 significantly correlated with Active Crescentic
Lesion Percentage (ACLP), but not Chronic Glomerular
Lesion Percentage (CGLP) (Table 2).
sVCAM-1 expression induced by IgA1 in HUVECs
At first, using HUVEC as a model of endothelial cells,
we tested the sVCAM-1 induction effect by IgA1 from
24 different subjects, which were 12 IgAN patients and
12 healthy volunteers. Compared to IgA1 from healthyTable 3 Plasma sVCAM-1 levels of IgAN patients with
different histological lesions, according to Oxford
classification
Oxford classification Number sVCAM-1 (ng/ml) p value
M 0 123 688.14±304.38 0.062
1 204 749.88±279.76
E 0 141 716.72±276.41 0.591
1 186 734.20±301.01
S 0 68 755.98±389.63 0.46
1 259 718.96±258.49
T 0 253 701.10±281.76 <0.001
1 39 699.27±213.43
2 35 941.97±339.95volunteers, IgA1 form IgAN patients showed a tendency
to increase the HUVECs supernatant sVCAM-1 expres-
sion, although did not reach the statistic significance
(Figure 2). Next, we detected the effect of IgA1 on the
sVCAM-1 expression in vitro. We found that IgA1
increased the sVCAM-1 expression in HUVECs culture
supernatant in a time- and dose-dependent manner. The
sVCAM-1 level in HUVECs supernatant significantly
elevated upon 48 h treatment with 200-400 ug/ml IgA1
(Figure 3a). And significantly increased supernatant
sVCAM-1 level could be detected at 48 h (Figure 3b).Figure 2 Scatter plot showing sVCAM-1 expressions in cultured
HUVECs under IgA1 from IgAN patients and healthy volunteers.
HUVECs were treated with 400 ug/ml IgA1 from healthy volunteers
(HC) or IgAN patients (IgAN). Compared to IgA1 from healthy
volunteers, IgA1 form IgAN patients showed a tendency to increase
the HUVECs supernatant sVCAM-1 expression (8.63±2.98 ng/ml
Vs 7.00±1.33 ng/ml, p=0.104).
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Patients with IgA nephropathy presented with variable
clinical findings, histological impairments and long-term
renal outcomes [18]. In the present study, we enrolled
327 patients with IgAN. Among them, 37.9% patients
presented with clinical hypertension at the time of renal
biopsy, which was well-approved to be an independent
risk factor for long-term renal outcome [19,20]; and
56.9% patients presented with histological endocapillary
hypercellularity, according to Oxford classification. This
supported previous observations that a great mass of
IgAN patients suffered vascular injury [21]. When we
used sVCAM-1 as the marker for vascular injury, espe-
cially inflammation injury, results showed that patients
with IgAN had significantly elevated plasma sVCAM-1
compared to healthy controls, which was in accordance
with previous reports in other IgAN patients’ cohorts
[11]. Similarly, in patients with lupus nephritis, in which
condition vascular injury were commonly reported,
sVCAM-1 levels were also significantly higher. But in
some other glomerular injury conditions, such as MCD
and MN, patients showed comparable sVCAM-1 levels
to healthy controls. Therefore, we regarded sVCAM-1 as
an indicator to vascular injury other than glomerular
injury.
Hypertension is a well accepted clinical finding for
vascular injury, but still over 70% patients in our present
study did not have this obvious symptom for vascular in-
jury. Although without hypertension, they also showed
significantly higher plasma sVCAM-1 compared to
healthy controls, while the patients with hypertension
presented with even higher plasma sVCAM-1. From
above findings, we suggested that plasma sVCAM-1 as
another marker for vascular injury, except for clinical
hypertension, and IgAN patients suffered vascular injury
are likely underestimated.Figure 3 sVCAM-1 expressions in cultured HUVECs under different do
treated with 25-400 ug/ml IgA1 for 48 hours. IgA1 induced the sVCAM-1 expres
Significantly increased supernatant sVCAM-1 level could be detected at 200 ug/
b. HUVECs were treated with 200 ug/ml IgA1 for 6–48 hours. IgA1 induced the
time-dependent manner. The sVCAM-1 level in HUVECs supernatant significantlIn addition, we described the significant association
between plasma sVCAM-1 level and clinical findings, in-
cluding eGFR and urinary protein excretion. D’Amico G
has already came to the concordance that impairment of
renal function, severe proteinuria, and arterial hyperten-
sion were the strongest and more reliable clinical predic-
tors of an unfavorable outcome after critical analysis of
results of 30 studies [22]. Since plasma sVCAM-1 level
in patients with IgAN associated with all the three risk
factors, we speculated the patients had higher plasma
sVCAM-1 levels would be in more severe clinical states
of IgAN.
Accordingly, we found the significantly different plasma
sVCAM-1 level among patients with different tubular atro-
phy/interstitial fibrosis lesion judged by Oxford classifica-
tion, an independent predictor of long-term renal outcome
measured by multivariate analysis. This result indicated that
plasma sVCAM-1 level in patients was a marker not only
for severe clinical state but also for severe histological lesion
of IgAN.
Oxford classification was derived from a group of IgAN
patients without most acute and rapidly progressive disease
courses and more than 50% of them without crescent, but
many of our IgAN patients in the present study had cres-
centic lesion in the glomeruli. Therefore, we used two vari-
ables, Active Crescentic Lesion Percentage (ACLP) and
Chronic Glomerular Lesion Percentage (CGLP), to roughly
distinguish the acute and chronic histological lesions. We
surprisingly found that only ACLP was significantly asso-
ciated with plasma sVCAM-1 level, not CGLP. It is import-
ant for us to point out that plasma sVCAM-1 level was a
marker for acute crescentic lesion in patients with IgAN.
Crescentic lesion is actually a kind of glomerular vascular
inflammation, so we considered elevated plasma sVCAM-1
level in patients with IgAN can at least partly ascribed to
glomerular vascular inflammation lesion.ses of IgA1 treatment for different time durations. a. HUVECs were
sion in cultured HUVECs supernatant in a dose-dependent manner.
ml and 400 ug/ml IgA1 (p=0.047 for 200 ug/ml, p<0.001 for 400 ug/ml).
sVCAM-1 expression in cultured HUVECs supernatant in a
y elevated upon 48 h treatment (p=0.009).
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elevated sVCAM-1 in IgAN. In recent years, lots of
efforts have been made to uncover the pathogenesis of
IgAN, and some significant progress has been achieved
in this field [23-25]. Increasing evidences indicated ab-
normal IgA1 molecules from IgAN patients to be the
initial factor to induce glomerular mesangial cells proli-
feration and secondary podocytes and tubular epithelial
cells injury [26-29]. Regarding to endothelial cells, less
evidence was available. We hypothesized that abnormal
IgA1 molecules from IgAN patients had unique activity
to promote sVCAM-1 expression from endothelial cells.
In order to exclude other reasons induced sVCAM-1
elevation in IgAN patients, such as inflammation
induced increased production by inflammatory cells and
eGFR induced decreased clearance, an in vitro cell
model was used. In the present study, we inferred that
IgA1 molecules from IgAN patients could promote
sVCAM-1 expression of endothelial cells for the follo-
wing three evidences: (1) the same amount of IgA1 from
IgAN patients showed a tendency to increase endothelial
sVCAM-1 expression; (2) patients with IgAN presented
with higher levels of IgA1 compared to healthy controls;
(3) IgA1 induced the sVCAM-1 increasing from
HUVECs in dose-dependent manner. However, it was
very possible that many other factors, like inflammatory
cells activation and decreased clearance due to impaired
renal function were also contributed to elevated
sVCAM-1 in IgAN patients, which we could not deter-
mine from present study.
Conclusions
In the present study, we used sVCAM-1 as a marker to
investigate vascular injury and its association with cli-
nical and pathological characteristics in patients with
IgAN. We found that the plasma levels of sVCAM-1 in
patients with IgAN were increased. And increased
plasma sVCAM-1 was associated with severe clinical
and pathological findings, especially acute glomerular
vascular inflammation lesion in patients with IgAN,
which might be partly resulted from the effect of IgA1
to endothelial cells.
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